0001477932-23-002536.txt : 20230414 0001477932-23-002536.hdr.sgml : 20230414 20230414120014 ACCESSION NUMBER: 0001477932-23-002536 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230228 FILED AS OF DATE: 20230414 DATE AS OF CHANGE: 20230414 EFFECTIVENESS DATE: 20230414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Innovation1 Biotech Inc. CENTRAL INDEX KEY: 0001629205 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822275255 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55852 FILM NUMBER: 23820334 BUSINESS ADDRESS: STREET 1: 179 RTE 46W, SUITE 15 #147 CITY: ROCKAWAY STATE: NJ ZIP: 07866 BUSINESS PHONE: 929-459-4966 MAIL ADDRESS: STREET 1: 179 RTE 46W, SUITE 15 #147 CITY: ROCKAWAY STATE: NJ ZIP: 07866 FORMER COMPANY: FORMER CONFORMED NAME: GridIron BioNutrients, Inc. DATE OF NAME CHANGE: 20180220 FORMER COMPANY: FORMER CONFORMED NAME: My Cloudz, Inc. DATE OF NAME CHANGE: 20141224 NT 10-Q 1 ivbt_nt10q.htm NT 10-Q ivbt_nt10q.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 12b-25

SEC FILE NUMBER

 

 

000-55852

 

NOTIFICATION OF LATE FILING

CUSIP NUMBER

 

 

39809D102

 

(Check One):

☐

Form 10-K

☐

Form 20-F

☐

Form 11-K

☒

Form 10-Q

 

☐

Form 10-D

☐

Form N-SAR

☐

Form N-CSR

 

 

 

 

For Period Ended: February 28, 2023        

 

 

 

 

☐

Transition Report on Form 10-K

 

☐

Transition Report on Form 20-F

 

☐

Transition Report on Form 11-K

 

☐

Transition Report on Form 10-Q

 

☐

Transition Report on Form N-SAR

 

 

 

 

For the Transition Period Ended: ___________________

 

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

 

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I -- REGISTRANT INFORMATION

 

Full Name of Registrant:

Innovation1 Biotech Inc.

 

 

Former Name if Applicable:

GridIron BioNutrients, Inc.

 

 

Address of Principal Executive Offices (Street and Number):

179 Rte 46W, Suite 15 #147, Rockaway, NJ 07866

 

 

 

   

PART II -- RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

 

☒

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

 

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

 

(c)

The accountant's statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

 

PART III -- NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Quarterly Report on Form 10-Q for the period ended February 28, 2023. Registrant expects to file the Quarterly Report on or before April 19, 2023.

 

PART IV -- OTHER INFORMATION

 

(1)

Name and telephone number of person to contact in regard to this notification:

 

Frederick E. Pierce

 

(929)

 

459-4966

Name

 

Area Code

 

Telephone Number

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes    ☐ No

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes    ☒ No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

2

 

   

Innovation1 Biotech Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on their behalf by the undersigned hereunto duly authorized.

 

Date: April 14, 2023

By:

/s/ Frederick E. Pierce

 

 

 

Frederick E. Pierce

Chief Executive Officer

 

 

Instruction: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

 

ATTENTION

 

INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).

 

 

3